Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
121 hedge funds and large institutions have $1.16B invested in Verve Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 37 reducing their positions, and 19 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
37% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $981K
32% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 37
27% more capital invested
Capital invested by funds: $912M → $1.16B (+$249M)
2.41% less ownership
Funds ownership: 102.34% → 99.94% (-2.4%)
3% less funds holding
Funds holding: 125 → 121 (-4)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$11.1M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$9.79M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$9.79M |
| 4 |
BlackRock
New York
|
+$5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.52M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$11.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.06M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.88M |
| 5 |
Citigroup
New York
|
-$6.74M |
VERV Hedge Fund Activity: Q2 2023 in Review
121 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2023, worth a combined $1.16B — up 27% from $912M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VERV and 15 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 49 added.
The largest buyer was ARK Investment Management, adding an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $13M.
- 121 institutional investors held Verve Therapeutics (VERV) as of Q2 2023, down from 125 in Q1 2023.
- Funds reported $1.16B of Verve Therapeutics stock for Q2 2023, up 27% quarter-over-quarter.
- 15 funds opened new Verve Therapeutics positions in Q2 2023 and 19 closed out, a net change of -4 holders.
- The largest Verve Therapeutics buyer in Q2 2023 was ARK Investment Management, an estimated $11.1M added.
- The largest Verve Therapeutics seller in Q2 2023 was Fidelity Investments, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2023.